Company: INTS
Filing Date: 2025-04-24
Form Type: S-1/A
Source: 0001628280-25-019491
Chunk: 27

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-04-24
Form: S-1/A
Chunk 27
---
|--------:|:----|:------------|--------:|
|                                                                                                                                                                         |     | -in thousands, except share and par value data |         |     |             |         |
|                                                                                                                                                                         |     | Actual                                         |         |     | As Adjusted |         |
| Cash and cash equivalents                                                                                                                                               |     | $                                              |   2,590 |     | $           |   5,090 |
| Shareholders’ equity                                                                                                                                                    |     |                                                |         |     |             |         |
| Common Stock; $0.0001 par value, 150,000,000 shares authorized, 15,122,873 shares issued and outstanding, actual, 17,430,565 shares issued and outstanding, as adjusted |     | $                                              |       2 |     | $           |       2 |
| Additional paid-in capital                                                                                                                                              |     | $                                              |  69,699 |     | $           |  72,199 |
| Accumulated deficit                                                                                                                                                     |     | $                                              | -66,783 |     | $           | -66,783 |
| Total shareholders’ equity                                                                                                                                              |     | $                                              |   2,918 |     | $           |   5,418 |
| Total capitalization                                                                                                                                                    |     | $                                              |   2,918 |     | $           |   5,418 |

The final public offering price will be determined through negotiation between us and the Placement Agents in the offering and may be at a discount to the current market price. Therefore, the assumed offering price used throughout this prospectus may not be indicative of the final public offering price. The as adjusted information set forth in the table above is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering determined at pricing.

A $1.00 increase or decrease in the assumed public offering price of $1.30 per share, the last reported sale price of our Common Stock on the Nasdaq Capital Market on April 23, 2025, would increase or decrease our cash and cash equivalents, additional paid in capital, and total stockholders’ equity on a pro forma as adjusted basis, by approximately $2.1 million, after deducting Placement Agents’ fees and estimated offering expenses payable by us, and assuming that the number of shares of Common Stock offered by us, as set forth on the cover page of this prospectus, remains the same.

An increase or decrease of 100